STOCK TITAN

Processa Pharmaceuticals (PCSA) Net Income by Year

PCSA NASDAQ

Processa Pharmaceuticals, Inc. reported a net loss of $13.6M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a $193.2M net loss. The table below carries 10 fiscal years, from 2016 to 2025, and the quarters Processa Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
Net Income -$13.6M
YoY n/m
5Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

PCSA Net Income by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-K
Net Income-$193.2M-$13.6Mn/m-$11.9Mn/m-$11.1Mn/m-$27.4Mn/m-$11.4Mn/m-$14.4Mn/m-$3.4Mn/m-$3.8Mn/m-$1.9Mn/m-$1.9M

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

PCSA Net Income by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Net Income-$183.2Mn/m-$3.3Mn/m-$3.4Mn/m-$3.4Mn/m-$3.4Mn/m-$3.9Mn/m-$2.8Mn/m-$2.7Mn/m-$3.4Mn/m-$3.0Mn/m-$2.7Mn/m-$2.4Mn/m

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Processa Pharmaceuticals, Inc. financials

Frequently Asked Questions

Processa Pharmaceuticals, Inc. reported a net loss of $13.6M in fiscal year 2025.

Processa Pharmaceuticals, Inc. (PCSA) reported a $11.9M net loss in fiscal year 2024 and a $13.6M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Processa Pharmaceuticals, Inc. (PCSA) reported a $193.2M net loss over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 10 fiscal years this page covers, Processa Pharmaceuticals, Inc. (PCSA) net income went from -$1.9M in fiscal year 2016 to -$13.6M in fiscal year 2025.

Processa Pharmaceuticals, Inc. (PCSA) reported -$183.2M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Processa Pharmaceuticals, Inc. (PCSA) reported on that line in every period on record.